The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the ...

A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...

A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...

Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon “without the intervention of the conflicted board ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...

ADRs fell ~6% on Tuesday after its board of directors declined to recommend Brookfield Asset Management's (NYSE:BAM) ...

Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer ...

GigaGen announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of the first ...

Brookfield Asset Management is considering a €6.45 billion ($6.9 billion) bid for Grifols SA, with the drug maker’s board set ...

An investigating magistrate at the Spanish High Court said on Tuesday it had opened an investigation into U.S.-based short ...